Doberman (Sweden)

Kunstig intelligens (AI) har raskt blitt en nøkkelteknologi som muliggjør betydelige forbedringer og innovasjoner i virksomheter. For å lykkes med AI-transformasjon bør bedrifter etablere en grunnmur for AI, utvikle en strategi, transformere forretningsfunksjoner, sikre tillit og ansvarlig håndtering av AI, samt heve kompetansen i arbeidsstyrken.

The article describes a tolerability study of the new drug Nephrospas, which contains telmisartan and excipients. The trial was conducted in cats with multiple daily administration at five times the therapeutic dose for 1 month (30 days).
 Two groups of animals were formed: experimental (10 cats) and control (7 cats). Animals of the experimental group were administered Nephrospas in a fivefold therapeutic dose of 0.5 ml/kg live weight of a cat orally during 30 days immediately after feeding. Animals of the control group were not administered the drug.
 
 Before the start of the experiment (day 0), on the 31st and 56th days of the experiment, weighing, thermometry, pulse and respiratory rates, blood pressure were determined, blood samples were taken for hematological studies (general clinical blood test, biochemical blood analysis), urine samples were taken for physical examination. chemical research.
 Based on the results of the conducted studies, it can be concluded that the drug Nephrospas is safe for cats when administered in excessive doses, as the use of the drug in a fivefold therapeutic dose does not adversely affect the general condition of animals, dynamics of body weight, blood pressure, does not change body temperature, morphological composition and biochemical parameters of blood, general clinical parameters of cat urine.